Microvascular and Fibrosis Imaging Study

NCT ID: NCT01758250

Last Updated: 2020-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

63 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical Coherence Tomography (OCT) will be used to assess differences in microvascular function and density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous involvement: systemic sclerosis (SSc), morphea, dermatomyositis, cutaneous lupus and vasculitis, 2) sickle cell disease (SCD) and 3) chronic graft-versus-host disease (GVHD) compared to healthy subjects. The microvascular changes will be compared to overall treatment response in patients with scleroderma and chronic GVHD as assessments will be made before and after the patients start treatment for their diseases and determine if these imaging techniques provide valuable and reproducible data when assessing a patient's response to treatment for those diseases. In addition, the application of Acoustic Radiation Force Impulse (ARFI) in determining cutaneous thickness in patients with SSc, GVHD and morphea will be evaluated.

The investigators hypothesize that the vascular and dermal structures are altered in patients with autoimmune disease, SCD and chronic GVHD. In addition, they hypothesize that imaging modalities such as LDF, LDI, OCT, NVC, OPSI and ARFI can quantify such structural alterations and can be used to 1) detect early disease activity, 2) quantify and assess response to therapy and 3) quantify and correlate with overall disease activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Diseases Sickle Cell Disease Chronic Graft Versus Host Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systemic Sclerosis

Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

GVHD

Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Undergoing HSCT

Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Controls

Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Sickle cell disease

Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Cutaneous fibrosing disorder

Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acoustic Radiation Force Impulse (ARFI)

Intervention Type OTHER

Laser Doppler Flowmetry (LDF)

Intervention Type OTHER

Laser Doppler Perfusion Imaging (LDI)

Intervention Type OTHER

Optical Coherence Tomography (OCT)

Intervention Type OTHER

Orthogonal Polarization Spectral Imaging (OPSI)

Intervention Type OTHER

Nail fold video capillaroscopy (NVC)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects above the age of 18 who are capable of giving informed consent with one of the following conditions: Scleroderma, Graft vs Host Disease, Sickle Cell Disease, Morphea, Connective Tissue Disease with cutaneous manifestations: cutaneous lupus, dermatomyositis, vasculitis, patients who are undergoing HSCT, or patients with a diagnosis of hematologic and non-hematologic malignancies without GVHD
* Control patients include normal healthy controls above the age of 18 who are capable of giving informed consent.

Exclusion Criteria

* Patients who experience discomfort, will be prone to experience discomfort or cannot tolerate the position required for the imaging studies.
* Subjects unable to provide informed consent.
* Smokers, patients unable to tolerate caffeine avoidance for the day of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Keith Sullivan, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Adela Cardones, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00039256

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.